CME accreditation will be provided by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). You will receive 1 hour of external CME credit for full attendance of the webinar, including completion of the pre-/post-CME test questions and evaluation.
Welcome and introductions
Current clinical landscape in anemic MF
- Current guidelines
- Momelotinib approval
- Treatment challenges and unmet needs
Optimal treatment sequencing in anemic MF
- When to initiate therapy
- First-line therapy considerations
- Relapsed and refractory disease
Ongoing clinical trials and key data
- NCT03194542 - A phase II study of luspatercept
- Pacritinib (e.g. NCT02055781)
Q&A Session
Evaluation/close
In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.